Phase 4 N=15 Depressed Mood Improvement Through Nicotine Dosing (Depressed MIND Study)
Major Depressive Disorder
Primary: Change in Total MADRS (Montgomery Asberg Depression Rating Scale) Score — -18.45 units on a scale — p=<0.001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=71 Oral Ketorolac for Pain Relief During IUD Insertion
Contraception
Primary: Pain Before, During and After IUD Placement — 4.1; 4.5; 0.4; 0.7 units on a scale — p=< 0.05
Phase 4 N=61 Biomarkers in Autism of Aripiprazole and Risperidone Treatment (BAART)
Autistic Disorder
Primary: Changes in the Irritability Subscale of the Larger ABC (Abberent Behavior Checklist) That Occur From Baseline to 10 Weeks — 12.7; 14.1 units on a scale
Phase 4 N=30 Emervel for the Correction of Lower Face Wrinkles & Folds
Nasolabial Folds · Marionette Lines · Wrinkles
Primary: Number of Subjects With Naturalness of Expression in Motion (2D Video) — 30 Participants
Phase 4 N=60 Comparison of Dysport Reconstitution at 1.5 mL and 2.5 mL for the Treatment of Moderate to Severe Glabellar Lines
Glabellar Lines · Wrinkles
Primary: Proportion of Composite Responders Who Achieve at Least a 1-point Reduction From Baseline in Glabellar Line Severity Score (GLSS) at Maximum Frown. — 27; 26 Participants
Phase 4 N=143 Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Elderly
Non-Small Cell Lung Cancer · Carcinoma · Squamous Cell Carcinoma
Primary: Percentage of Participants With Either Peripheral Neuropathy ≥ Grade 2 or Myelosuppression Adverse Events (AEs) ≥ Grade 3 Based on Local Laboratory Values — 76.5; 77.1…
Phase 4 N=3,939 Safety of One Dose of Meningococcal ACWY Conjugate Vaccine in Subjects From 2 Months to 55 Years of Age in the Republic of South Korea
Meningococcal Disease
Primary: Number of Subjects Reporting Any Local and Systemic Solicited Adverse Events (AEs) — 67; 32; 28; 110 Participants
Phase 4 N=449 Understanding Disparities in Quitting in African American and White Smokers
Smoking Cessation
Primary: Number of Participants With Cotinine-verified 7-day Point Prevalence Smoking Abstinence at Week 26 — 32; 55 Participants
Phase 4 N=200 A Study of Rebif® in Subjects With Relapsing Multiple Sclerosis
Multiple Sclerosis, Relapsing-Remitting
Primary: Difference in Multiple Sclerosis Treatment Concern Questionnaire (MSTCQ) Flu Like Symptom (FLS) Score Between Rebif Morning Administration and Rebif Evening…
Phase 4 N=26 Reduction of Bladder Injection Pain With Belladonna Opiate Suppository
Overactive Bladder · Urinary Urge Incontinence · Urinary Bladder, Neurogenic
Primary: Change in Bladder Injection Pain — 5; 4; 5 units on a scale — p=0.94
Phase 4 N=40 Characterization of Changes in Ventricular Mechanics in Response to Lexiscan Stress Using Tagged Cine Cardiac Magnetic Resonance Imaging
Coronary Artery Disease
Primary: RADIAL STRAIN — 0.158; 0.149; 0.150; 0.190 unitless (strain) — p=0.001
Phase 4 N=568 A Phase 4 Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Male Subjects With Overactive Bladder (OAB) Symptoms, While Taking the Alpha Blocker for Benign Prostatic Hypertrophy (BPH)
Overactive Bladder
Primary: Change From Baseline to End of Treatment (EoT) in Mean Number of Micturitions Per 24 Hours — -0.90; -1.35 micturitions — p=<0.001
Phase 4 N=18 Prophylactic Antibiotics for Prevention of Wound Complications Following Vulvectomy
Wound Infection
Primary: Wound Complications — 3; 2 Participants
Phase 4 N=806 Long-Term Safety of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
Glaucoma · Ocular Hypertension
Primary: Percentage of Participants Reporting One or More Treatment-Related Ocular Surface Adverse Events — 33.3; 37.7 percentage of participants — p=0.148
Phase 4 N=68 The Effects of Vitamin D on Angiogenic Factors in Women With Polycystic Ovary Syndrome
Polycystic Ovary Syndrome · Vitamin D Deficiency
Primary: Effect of Vitamin D on Angiogenic Factors — 6.7; 5.6; 5.9; 5.5 ratio